<p>(A, B) Bar diagrams showing the absorption rates determined with colorimetric BrdU Cell Proliferation ELISA. Dsg2-depleted MeWo (“Dsg2 Ko”; A) and Dsg2-depleted C32 cells (B) were compared to cells treated with non-targeting siRNA (“nt Ko”) and to untreated cells. Pairwise t-tests gave no significant differences with respect to absorption, indicating similar proliferation rates in all probes. (C) MTT assay comparing the viability of Dsg2-depleted MeWo and C32 cells to non-targeting siRNA-treated and untreated controls at densities of 10000 cells/well (white bars) or 15000 cells/well (grey bars). Quantification and normalization showed no significant differences between Dsg2 Ko and nt Ko cells. Analysis of untreated cells indicated increa...
<p>(A) Primary human fibroblasts and 1205Lu melanoma cells were treated with the indicated siRNAs an...
<p>SPHK1 (panel A) and SPHK2 (panel B) as well as the cytotoxic controls PLK1 and POLR2A were target...
<p>Viability was measured after 45% of vehicle (0.05% DMSO)-treated control. For comparison, the leu...
<p>(A-F) Transwell migration assays comparing Dsg2-depleted (“Dsg2 Ko”) and non-targeting siRNA-trea...
<p>(A) Immunoblots showing efficient Dsg2 depletion in MeWo and C32 melanoma cells. Equal amounts of...
<p>(A, B) Transwell invasion assays of Dsg2-depleted (“Dsg2 Ko”) or non-targeting siRNA-treated (“nt...
<p>(A, B) Real time PCR showing significantly increased SgII mRNA in subconfluent but not in conflue...
<p>(A) Cell proliferation rate of melanoma cells treated with catalase for 24 h, relative to control...
<p>(<b>A</b>) Stable infected Mel.7 cells (n.s., sh-catu2) were treated with 0, 5, 10 and 20 μg/ml c...
<p>Anchorage-dependent (<b>A</b>) and anchorage-independent (<b>B</b>) cell growth was investigated ...
<p>Viability of each cell line is indicated in the histogram. The results are expressed as per cents...
<p><b>A.</b> Effect of BRG1 or MITF depletion on DNA content profile determined by flow cytometry in...
<p>(A–D) Intracellular ROS levels decreased in melanoma cells either when treated with catalase or w...
In vivo tumor growth assessment and RNA-seq characterization of murine BrafV600E melanoma cells with...
<p>(A) shRNA-mediated knockdown of <i>DRG-1</i>. <i>DRG-1</i>-specific lentiviral shRNAs were constr...
<p>(A) Primary human fibroblasts and 1205Lu melanoma cells were treated with the indicated siRNAs an...
<p>SPHK1 (panel A) and SPHK2 (panel B) as well as the cytotoxic controls PLK1 and POLR2A were target...
<p>Viability was measured after 45% of vehicle (0.05% DMSO)-treated control. For comparison, the leu...
<p>(A-F) Transwell migration assays comparing Dsg2-depleted (“Dsg2 Ko”) and non-targeting siRNA-trea...
<p>(A) Immunoblots showing efficient Dsg2 depletion in MeWo and C32 melanoma cells. Equal amounts of...
<p>(A, B) Transwell invasion assays of Dsg2-depleted (“Dsg2 Ko”) or non-targeting siRNA-treated (“nt...
<p>(A, B) Real time PCR showing significantly increased SgII mRNA in subconfluent but not in conflue...
<p>(A) Cell proliferation rate of melanoma cells treated with catalase for 24 h, relative to control...
<p>(<b>A</b>) Stable infected Mel.7 cells (n.s., sh-catu2) were treated with 0, 5, 10 and 20 μg/ml c...
<p>Anchorage-dependent (<b>A</b>) and anchorage-independent (<b>B</b>) cell growth was investigated ...
<p>Viability of each cell line is indicated in the histogram. The results are expressed as per cents...
<p><b>A.</b> Effect of BRG1 or MITF depletion on DNA content profile determined by flow cytometry in...
<p>(A–D) Intracellular ROS levels decreased in melanoma cells either when treated with catalase or w...
In vivo tumor growth assessment and RNA-seq characterization of murine BrafV600E melanoma cells with...
<p>(A) shRNA-mediated knockdown of <i>DRG-1</i>. <i>DRG-1</i>-specific lentiviral shRNAs were constr...
<p>(A) Primary human fibroblasts and 1205Lu melanoma cells were treated with the indicated siRNAs an...
<p>SPHK1 (panel A) and SPHK2 (panel B) as well as the cytotoxic controls PLK1 and POLR2A were target...
<p>Viability was measured after 45% of vehicle (0.05% DMSO)-treated control. For comparison, the leu...